Susquehanna Fundamental Investments, LLC Autolus Therapeutics PLC Transaction History

Susquehanna Fundamental Investments, LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$2.04 - $3.76 $98,430 - $181,420	-48,250 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$3.52 - $5.46 $63,631 - $98,700	-18,077 Reduced 27.25%	48,250 $201,000
Q4 2021 Feb 14, 2022	SELL	$5.1 - $7.0 $169,947 - $233,261	-33,323 Reduced 33.44%	66,327 $344,000
Q3 2021 Nov 15, 2021	BUY	$5.32 - $7.37 $195,244 - $270,479	36,700 Added 58.3%	99,650 $653,000
Q2 2021 Aug 11, 2021	BUY	$4.78 - $7.96 $300,901 - $501,082	62,950 New	62,950 $418,000

104

163M

2.8K

13.4K

Ticker AUTL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 90,909,800
Market Cap $205M
Description
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which...

Get notified when there are updates to the investment portfolio of Susquehanna Fundamental Investments, LLC, based on Form 13F filings with the SEC.

Stay updated on Susquehanna Fundamental Investments, LLC with notifications on news.